
News and Press Releases
10/23/2014
Hospira Recalls Dozens of Product Lots
Hospira recently announced the recall of one lot of lidocaine hydrochloride injection (PDF) and multiple lots of 12 injectable products packaged in flexible i.v. containers (PDF) . According to Hospira, lot 40-316-DK of 1% lidocaine hydrochloride injection packaged in 30-mL single-dose vials, was10/22/2014
FDA, Advisers Mull "Polypill" for Patients With Cardiovascular Disease
The decade-old concept of combination therapy packaged in a so-called polypill for patients with cardiovascular disease received a mostly favorable reception in September from FDA officials and agency advisers. "I think, really, it should be widely used for secondary prevention," said Stanford Un10/22/2014
DEA Reschedules Hydrocodone, Makes Changes to Controlled Substance Disposal
The Drug Enforcement Administration (DEA) in late August successfully concluded its 10-year campaign to move hydrocodone-containing combination products from Schedule III of the Controlled Substances Act to the more tightly regulated Schedule II. DEA stated that the change affects several hundred10/20/2014
Nintedanib Approved as Idiopathic Pulmonary Fibrosis Treatment
FDA last week approved the marketing of nintedanib, or Ofev, for the treatment of idiopathic pulmonary fibrosis. The disease, which worsens over time, damages lungs to the point that patients commonly are short of breath and have difficulty engaging in everyday activities, the agency said. Patie10/16/2014
Pirfenidone Approved for Treatment of Idiopathic Pulmonary Fibrosis
FDA on October 15 approved the marketing of pirfenidone, or Esbriet, for the treatment of idiopathic pulmonary fibrosis. The disease impairs lung function and has no cure, according to the National Heart, Lung, and Blood Institute. In three placebo-controlled studies involving a total of 1247 pa10/16/2014
New Resource Center, Connect Community Pull Together Ebola Preparedness Materials
ASHP has created a new resource center to help pharmacists contribute to the emergency preparedness efforts at their practice sites in the wake of the recent Ebola outbreak. The site includes links to resources available from the U.S. Centers for Disease Control and Prevention (CDC), the National10/14/2014
FDA Approves Contrast Agent to Enhance Echocardiograms
FDA on October 10 approved the marketing of sulfur hexafluoride lipid microspheres for use during echocardiography to improve images of the left ventricular chamber and endocardial border in patients whose previous echocardiograms of those areas have been suboptimal. The product, by Bracco Diagnos10/14/2014